Key result
Review highlights novel molecular compounds targeting pulmonary vascular remodeling to treat PAH.
Why the study?
Current pulmonary arterial hypertension therapies mainly target vasodilation without affecting pathological vascular changes, creating a need for novel compounds that antagonize pulmonary vascular remodeling.
This review highlights the shift in PAH treatment development from pulmonary vasodilators to novel compounds targeting underlying pulmonary vascular remodeling.
Answers are grounded in this paper and cite their sources.
Novel remodeling-targeted agents in PAH remain investigational; leaves open clinical translation pending prospective trials.
Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms. Since current available treatments mainly target pulmonary vasodilation, but lack an effect on the pathological changes that develop in the pulmonary vasculature, there is need to develop novel therapeutic compounds aimed at antagonizing the pulmonary vascular remodeling. This review presents the main molecular mechanisms involved in the pathobiology of PAH, discusses the new molecular compounds currently being developed for the medical treatment of PAH and assesses their potential future role in the therapeutic algorithms of PAH.
No takes yet. Share an insight, caveat, or question.
Miguel et al. (2023) conducted a review in Pulmonary arterial hypertension (PAH). Novel molecular compounds targeting pulmonary vascular remodeling vs. Current available treatments (pulmonary vasodilation) was evaluated. This review discusses novel molecular compounds currently in development that target pulmonary vascular remodeling for the medical treatment of pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: